INVO vs. DRIO, PYPD, FEMY, ALUR, NEPH, RVP, ADGM, NXGL, GBS, and PETV
Should you be buying INVO Bioscience stock or one of its competitors? The main competitors of INVO Bioscience include DarioHealth (DRIO), PolyPid (PYPD), Femasys (FEMY), Allurion Technologies (ALUR), Nephros (NEPH), Retractable Technologies (RVP), Adagio Medical (ADGM), NEXGEL (NXGL), GBS (GBS), and PetVivo (PETV). These companies are all part of the "surgical & medical instruments" industry.
INVO Bioscience vs.
DarioHealth (NASDAQ:DRIO) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends.
In the previous week, DarioHealth had 5 more articles in the media than INVO Bioscience. MarketBeat recorded 6 mentions for DarioHealth and 1 mentions for INVO Bioscience. INVO Bioscience's average media sentiment score of 1.53 beat DarioHealth's score of -0.30 indicating that INVO Bioscience is being referred to more favorably in the news media.
33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are owned by institutional investors. 10.9% of DarioHealth shares are owned by company insiders. Comparatively, 3.5% of INVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
INVO Bioscience has a net margin of -122.79% compared to DarioHealth's net margin of -205.62%. INVO Bioscience's return on equity of 0.00% beat DarioHealth's return on equity.
DarioHealth has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.
INVO Bioscience has lower revenue, but higher earnings than DarioHealth.
DarioHealth received 233 more outperform votes than INVO Bioscience when rated by MarketBeat users. Likewise, 67.04% of users gave DarioHealth an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote.
DarioHealth presently has a consensus target price of $2.00, suggesting a potential upside of 189.81%. Given DarioHealth's stronger consensus rating and higher possible upside, equities research analysts plainly believe DarioHealth is more favorable than INVO Bioscience.
Summary
DarioHealth beats INVO Bioscience on 10 of the 16 factors compared between the two stocks.
Get INVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for INVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
INVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:INVO) was last updated on 5/22/2025 by MarketBeat.com Staff
